Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Komiya, Chikara ^a   Tsuchiya, Kyoichiro ^a   Shiba, Kumiko ^a   Miyachi, Yasutaka ^a   Furuke, Shunsaku ^a   Shimazu, Noriko ^a   Yamaguchi, Shinobu ^a   Kanno, Kazuo ^b   Ogawa, Yoshihiro ^a,c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Kanno Clinic   (Japan)

^c JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IPRAGLIFLOZIN; ANTIDIABETIC AGENT; GLUCOSE; GLUCOSIDE; LEPTIN; LIPID; SLC5A2 PROTEIN, HUMAN; SLC5A2 PROTEIN, MOUSE; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; EPIDIDYMIS FAT; FAT MASS; FATTY LIVER; GENE INDUCTION; HOMEOSTASIS; HYPERPHAGIA; INFLAMMATION; INSULIN RESISTANCE; LIPID STORAGE; LIPOGENESIS; LIVER DYSFUNCTION; LIVER WEIGHT; MACROPHAGE; MALE; MARKER GENE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; WEIGHT REDUCTION; ADIPOSE TISSUE; ADULT; ANIMAL; BODY WEIGHT; BODY WEIGHT LOSS; C57BL MOUSE; CHEMICALLY INDUCED; COMPLICATION; DEFICIENCY; DRUG EFFECT; EPIDIDYMIS; HUMAN; LIPID DIET; LIVER; METABOLISM; MOUSE MUTANT; NONALCOHOLIC FATTY LIVER; ORGAN SIZE; PATHOLOGY; PRECLINICAL STUDY;

ADIPOSE TISSUE; ADULT; ANIMALS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DRUG EVALUATION, PRECLINICAL; ENERGY INTAKE; EPIDIDYMIS; GLUCOSE; GLUCOSIDES; HUMANS; HYPERPHAGIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LEPTIN; LIPIDS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; ORGAN SIZE; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; THIOPHENES; WEIGHT LOSS;

EID: 84961615237     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151511     Document Type: Article

References (41)

1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014; 103:137-149. doi: 10.1016/j.diabres.2013.11.002 PMID: 24630390
2. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011; 377: 557-567. doi: 10.1016/S0140-6736(10)62037-5 PMID: 21295846
3. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006; 444: 840-846. PMID: 17167471
4. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375: 2215-2222. doi: 10.1016/S0140-6736(10)60484-9 PMID: 20609967
5. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364: 829-841. doi: 10.1056/NEJMoa1008862 PMID: 21366474
6. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015; 313: 2263-2273. doi: 10.1001/jama.2015.5370 PMID: 26057287
7. Targher G, Byrne CD. Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013; 98: 483-495. doi: 10.1210/jc.2012-3093 PMID: 23293330
8. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012; 56: 255-266. doi: 10.1016/j.jhep.2011.06.010 PMID: 21723839
9. Chao EC, Henry RR. SGLT2 inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010; 9: 551-559. doi: 10.1038/nrd3180 PMID: 20508640
10. Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2(SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther. 2013; 139: 51-59. doi: 10.1016/j.pharmthera.2013.04.003 PMID: 23563279
11. Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013; 15: 372-382. doi: 10.1111/dom.12054 PMID: 23279307
12. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015; 38:1730-1735. doi: 10.2337/dc15-0355 PMID: 26180105
13. Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity. 2012; 20:1645-1652. doi: 10.1038/oby.2012.59 PMID: 22402735
14. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013; 715: 246-255. doi: 10.1016/j.ejphar.2013.05.014 PMID: 23707905
15. Qiang S, Nakatsu Y, Seno Y, Fujishiro M, Sakoda H, Kushiyama A, et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr. 2015; 7:104. doi: 10.1186/s13098-015-0102-8 PMID: 26594248
16. Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol. 2014; 34:1155-1161. doi: 10.1161/ATVBAHA.114.303034 PMID: 24743428
17. Murano I, Barbatelli G, Parisani V, Latini C, Muzzonigro G, Castellucci M, et al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res. 2008; 49:1562-1568. doi: 10.1194/jlr.M800019-JLR200 PMID: 18390487
18. Tanaka M, Ikeda K, Suganami T, Komiya C, Ochi K, Shirakawa I, et al. Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis. Nat Commun. 2014; 5: 4982. doi: 10.1038/ncomms5982 PMID: 25236782
19. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005; 46: 2347-2355. PMID: 16150820
20. Obata A, Kubota N, Kubota T, Iwamoto M, Sato H, Sakurai Y, et al. Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice. Endocrinology. 2015; in press.
21. Nakano S, Katsuno K, Isaji M, Nagasawa T, Buehrer B, Walker S, et al. Remogliflozin etabonate improves fatty liver disease in diet-induced obese male mice. J Clin Exp Hepatol. 2105; 5:190-198. doi: 10.1016/j.jceh.2015.02.005 PMID: 26628836
22. Watanabe Y, Nakayama K, Taniuchi N, Horai Y, Kuriyama C, Ueta K, et al. Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes. PLOS ONE. 2015; 10: e0116851. doi: 10.1371/journal.pone.0116851 PMID: 25615826
23. Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, Lipovsky AI, et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab. 2011; 14: 21-32. doi: 10.1016/j.cmet.2011.06.002 PMID: 21723501
24. Hasty AH, Shimano H, Yahagi N, Amemiya-Kudo M, Perrey S, Yoshikawa T, et al. Sterol regulatory element-binding protein-1 is regulated by glucose at the transcriptional level. J Biol Chem. 2000; 275: 31069-31077. PMID: 10913129
25. Matsuzaka T, Shimano H, Yahagi N, Amemiya-Kudo M, Okazaki H, Tamura Y, et al. Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocin-treated mice. Diabetes. 2004; 53: 560-569. PMID: 14988238
26. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, Yoshikawa T, et al. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem. 2002; 277:19353-19357. PMID: 11923308
27. Savage DB, Choi CS, Samuel VT, Liu ZX, Zhang D, Wang A, et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest. 2006; 116: 817-824. PMID: 16485039
28. Strissel KJ, Stancheva Z, Miyoshi H, Perfield JW 2nd, De Furia J, Jick Z, et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes. 2007; 56: 2910-2918. PMID: 17848624
29. Khan T, Muise ES, Iyengar P, Wang ZV, Chandalia M, Abate N, et al. Metabolicdysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol. 2009; 29:1575-1591. doi: 10.1128/MCB.01300-08 PMID: 19114551
30. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004; 350:1220-1234. PMID: 15028826
31. Morley TS, Xia JY, Scherer PE. Selective enhancement of insulin sensitivity in the mature adipocyte is sufficient for systemic metabolic improvements. Nat Commun. 2015; 6: 7906. doi: 10.1038/ncomms8906 PMID: 26243466
32. Lin Y, Berg AH, Iyengar P, Lam TK, Giacca A, Combs TP, et al. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem. 2005; 280: 4617-4626. PMID: 15536073
33. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014; 124: 499-508. doi: 10.1172/JCI72227 PMID: 24463454
34. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014; 124: 509-514. doi: 10.1172/JCI70704 PMID: 24463448
35. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thevenet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015; 21: 512-517. doi: 10.1038/nm.3828 PMID: 25894829
36. Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev. 2007; 28:253-283. PMID: 17409288
37. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382: 941-950. doi: 10.1016/S0140-6736(13)60683-2 PMID: 23850055
38. Del Prato S, Nauck M, Duran-Garcia S, Maffei L, Rohwedder K, Theuerkauf A, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab. 2015; 17: 581-590. doi: 10.1111/dom.12459 PMID: 25735400
39. Iizuka T, Iemitsu K, Takihata M, Takai M, Nakajima S, Minami N, et al. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes: interim outcome of the ASSIGN-K study. J Clin Med Res. 2016; 8: 116-125. doi: 10.14740/jocmr2417w PMID: 26767080
40. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 375: 2223-2233. doi: 10.1016/S0140-6736(10)60407-2 PMID: 20609968
41. Waterson MJ, Horvath TL. Neuronal Regulation of Energy Homeostasis: Beyond the Hypothalamus and Feeding. Cell Metab. 2015; 22: 962-970. doi: 10.1016/j.cmet.2015.09.026 PMID: 26603190